Compare IMXI & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMXI | PLRX |
|---|---|---|
| Founded | 1994 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 469.3M | 81.1M |
| IPO Year | 2016 | 2020 |
| Metric | IMXI | PLRX |
|---|---|---|
| Price | $15.80 | $1.36 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 3 | 4 |
| Target Price | ★ $16.67 | $2.67 |
| AVG Volume (30 Days) | 320.6K | ★ 558.0K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.97 |
| EPS | ★ 1.08 | N/A |
| Revenue | ★ $319,601,000.00 | N/A |
| Revenue This Year | $0.28 | N/A |
| Revenue Next Year | $0.41 | N/A |
| P/E Ratio | $14.63 | ★ N/A |
| Revenue Growth | ★ 16.68 | N/A |
| 52 Week Low | $8.58 | $1.09 |
| 52 Week High | $15.90 | $1.95 |
| Indicator | IMXI | PLRX |
|---|---|---|
| Relative Strength Index (RSI) | 55.64 | 56.43 |
| Support Level | $15.73 | $1.12 |
| Resistance Level | $15.81 | $1.36 |
| Average True Range (ATR) | 0.04 | 0.07 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 41.18 | 87.50 |
International Money Express Inc is an omnichannel money remittance services company focused on the United States of America to Latin America and the Caribbean corridor, which includes Mexico, Central and South America and the Caribbean. The company offers wire transfer, money order, Foreign exchange, and cash checking services, while the majority of the revenue is derived from wire transfer and money order fees. The firm's business is organized around one reportable segment that provides money remittance services between the U.S. and Canada to Mexico, Guatemala, and other countries in Latin America, Africa, and Asia.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.